デフォルト表紙
市場調査レポート
商品コード
1484115

バイオシミラー/フォローオンバイオロジクス市場:2024-2034年

Biosimilars and Follow-On Biologics Market Report 2024-2034

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 391 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=206.60円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

バイオシミラー/フォローオンバイオロジクス市場:2024-2034年
出版日: 2024年05月23日
発行: Visiongain Reports Ltd.
ページ情報: 英文 391 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオシミラー/フォローオンバイオロジクスの市場規模は、2034年にかけてCAGR 14.8%で成長すると予測されています。

慢性疾患治療薬の需要の増加:

糖尿病、関節リウマチ、各種癌などの慢性疾患はますます増加しており、効果的な長期治療の必要性が高まっています。この急増は、高齢化、生活習慣病の増加、早期発見と長期の治療を可能にする医学の進歩など、さまざまな要因によって推進されています。

疾患のメカニズムに対する理解が深まる中で、バイオロジクスは医療の革新の最前線に立ち、以前は治療不可能であった病態の患者に希望をもたらしています。さらに、慢性疾患の積極的な管理を提唱するヘルスケアの意識の高まりと発展的な政策も、バイオロジクスに対する需要の増加にさらに寄与しています。

バイオシミラーの承認に有利な規制政策:

世界の規制当局は、バイオシミラーが品質、安全性、有効性に関する厳格な基準を満たすことを保証し、バイオシミラーの承認に向けた明確で透明性の高い道筋を確立することの重要性を認識しています。

有利な規制政策の重要な要素の一つは、バイオシミラーのユニークな特性に合わせた特定のガイドラインと枠組みの確立です。比較的容易に複製できる低分子医薬品とは異なり、バイオロジクスは生きた細胞内で生産される巨大で複雑な分子であるため、その開発と特性評価はより困難なものとなります。規制上の経路では、バイオシミラー医薬品メーカーがリファレンスバイオロジクスの既存の臨床データに依存することを許可しており、これが承認プロセスを迅速化する一方で、類似性と安全性の証明に関しては強固な比較分析試験と臨床試験を必要とします。明確な期待と要件を示すことで、これらのガイドラインは、メーカーが規制プロセスをより効率的かつ効果的に進めることを可能にし、バイオシミラーの開発と承認を加速させています。

当レポートでは、世界のバイオシミラー/フォローオンバイオロジクスの市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主要調査結果
  • 市場力学
    • 市場推進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • バイオシミラー収益:地域別
  • バイオシミラーの最新の承認予定
  • 最新のバイオシミラー製品取引
  • 承認済みバイオシミラーのリスト
  • 最近発売されたバイオシミラーのリスト
  • ポーターのファイブフォース分析
  • PEST分析

第4章 バイオシミラー/フォローオンバイオロジクス市場の分析:製品タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 組み換え非糖化タンパク質
    • 製品タイプ別
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
    • ヒト成長ホルモン
    • 顆粒球コロニー刺激因子 (フィルグラスチム)
    • インスリン
    • インターフェロン
  • 組み換え糖化タンパク質
    • 製品タイプ別
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
    • エリスロポエチン
    • モノクローナル抗体
    • フォリトロピン
    • 低分子量ヘパリン

第5章 バイオシミラー/フォローオンバイオロジクス市場の分析:用途別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 血液
    • タイプ別
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
    • 好中球減少症
    • 貧血
    • その他
  • 腫瘍
    • タイプ別
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
    • 肺癌
    • 脳腫瘍
    • 乳癌
    • 子宮頸癌
    • 大腸癌
    • 白血病
    • その他
  • 自己免疫疾患
    • タイプ別
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
    • 関節炎
    • 炎症性腸疾患
    • 乾癬
    • その他
  • 成長ホルモン欠乏症
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
  • 糖尿病
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第6章 バイオシミラー/フォローオンバイオロジクス市場の分析:技術別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 組み換えDNA (rDNA) 技術
  • モノクローナル抗体 (MAb) 技術
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第7章 バイオシミラー/フォローオンバイオロジクス市場の分析:メーカー別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 受託研究・受託製造サービス
  • 社内
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第8章 バイオシミラー/フォローオンバイオロジクス市場の分析:地域別

  • 主要調査結果
  • 市場規模の推移・予測

第9章 北米のバイオシミラー/フォローオンバイオロジクス市場の分析

第10章 欧州のバイオシミラー/フォローオンバイオロジクス市場の分析

第11章 アジア太平洋のバイオシミラー/フォローオンバイオロジクス市場の分析

第12章 ラテンアメリカのバイオシミラー/フォローオンバイオロジクス市場の分析

第13章 中東・アフリカのバイオシミラー/フォローオンバイオロジクス市場の分析

第14章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • Amgen Inc.
  • Apotex (Apobiologix)
  • Biocad
  • Biocon Biologics Ltd.
  • Bio-Thera Solutions
  • Coherus Biosciences
  • Dr. Reddy's Laboratories
  • Fresenius Kabi (Fresenius SE &Co. KGaA)
  • Intas Pharma
  • Pfizer
  • Reliance Life Sciences
  • Samsung Bioepis (Samsung Biologics)
  • Sandoz Group AG
  • Teva Pharmaceuticals Industries Ltd.

第15章 総論・提言

  • Visiongainによる総論
  • 参入企業への提言
図表

List of Tables

  • Table 1 Biosimilars and Follow-On Biologics Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Cost comparison of a Biosimilars and their reference products
  • Table 3 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7 Worldwide Biosimilars Revenue 2023 (US$ Million)
  • Table 8 United States Biosimilars Revenue 2023 (US$ Million)
  • Table 9 Japan Biosimilars Revenue 2023 (US$ Million)
  • Table 10 United States Biosimilars Latest Expected Approvals
  • Table 11 Europe Biosimilars Latest Expected Approvals
  • Table 12 Europe Biosimilars Latest Expected Approvals
  • Table 13 List of Approved Biosimilars
  • Table 14 List of Recently Launched Biosimilars
  • Table 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 16 Recombinant Non-Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 18 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 19 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 20 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 21 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 22 Recombinant Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 23 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 25 Recombinant Glycosylated Proteins Segment Market Forecast by Monoclonal Antibodies, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 26 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 28 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 29 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 30 Hematology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 31 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 32 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 33 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 Oncology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 36 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 37 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 38 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 39 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 40 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 41 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 42 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 43 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 Autoimmune Disease Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 45 Autoimmune Disease Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Autoimmune Disease Segment Market Forecast by Arthritis, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 47 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 48 Autoimmune Disease Segment Market Forecast by Inflammatory Bowel Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 50 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 51 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 52 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 54 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 55 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 56 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 57 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 59 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 62 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 63 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 64 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 65 North America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 66 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 67 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 69 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 71 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 72 Europe Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 73 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 74 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 75 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 76 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 77 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 78 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 79 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 80 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 81 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 82 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 83 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 84 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 85 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 86 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 87 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 88 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 89 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 90 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 91 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 92 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 93 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 94 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 95 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 96 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 97 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 98 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 99 Latin America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 100 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 101 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 102 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 103 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 104 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 105 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 106 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 107 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 108 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 109 MEA Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 110 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 111 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 112 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 113 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 114 Strategic Outlook
  • Table 115 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Amgen Inc.: Product Benchmarking
  • Table 117 Amgen Inc.: Strategic Outlook
  • Table 118 Apotex (Apobiologix): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Apotex (Apobiologix): Product Benchmarking
  • Table 120 Apotex (Apobiologix): Strategic Outlook
  • Table 121 Biocad: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Biocad: Product Benchmarking
  • Table 123 Biocad: Strategic Outlook
  • Table 124 Biocon Biologics Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 Biocon Biologics Ltd.: Product Benchmarking
  • Table 126 Biocon Biologics Ltd.: Strategic Outlook
  • Table 127 Bio-Thera Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Bio-Thera Solutions: Product Benchmarking
  • Table 129 Bio-Thera Solutions: Strategic Outlook
  • Table 130 Coherus Biosciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Coherus Biosciences: Product Benchmarking
  • Table 132 Coherus Biosciences: Strategic Outlook
  • Table 133 Dr. Reddy's Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Dr. Reddy's Laboratories: Product Benchmarking
  • Table 135 Dr. Reddy's Laboratories: Strategic Outlook
  • Table 136 Fresenius Kabi (Fresenius SE & Co. KGaA): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Fresenius Kabi (Fresenius SE & Co. KGaA): Product Benchmarking
  • Table 138 Fresenius Kabi (Fresenius SE & Co. KGaA): Strategic Outlook
  • Table 139 Intas Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 Intas Pharma: Product Benchmarking
  • Table 141 Intas Pharma: Strategic Outlook
  • Table 142 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Pfizer: Product Benchmarking
  • Table 144 Pfizer: Strategic Outlook
  • Table 145 Reliance Life Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Reliance Life Sciences: Product Benchmarking
  • Table 147 Reliance Life Sciences: Strategic Outlook
  • Table 148 Samsung Bioepis (Samsung Biologics): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Samsung Bioepis (Samsung Biologics): Product Benchmarking
  • Table 150 Samsung Bioepis (Samsung Biologics): Strategic Outlook
  • Table 151 Sandoz Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 152 Sandoz Group AG: Product Benchmarking
  • Table 153 Sandoz Group AG: Strategic Outlook
  • Table 154 Teva Pharmaceuticals Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 Teva Pharmaceuticals Industries Ltd.: Product Benchmarking
  • Table 156 Teva Pharmaceuticals Industries Ltd.: Strategic Outlook

List of Figures

  • Figure 1 Biosimilars and Follow-On Biologics Market Segmentation
  • Figure 2 Biosimilars and Follow-On Biologics Market by Product Type: Market Attractiveness Index
  • Figure 3 Biosimilars and Follow-On Biologics Market Application: Market Attractiveness Index
  • Figure 4 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
  • Figure 5 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
  • Figure 6 Biosimilars and Follow-On Biologics Market Attractiveness Index by Region
  • Figure 7 Biosimilars and Follow-On Biologics Market: Market Dynamics
  • Figure 8 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 9 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 10 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 11 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 12 Biosimilars and Follow-On Biologics Market: Porter's Five Forces Analysis
  • Figure 13 Biosimilars and Follow-On Biologics Market: PEST Analysis
  • Figure 14 Biosimilars and Follow-On Biologics Market by Product type: Market Attractiveness Index
  • Figure 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 16 Biosimilars and Follow-On Biologics Market Share Forecast by Product type, 2024, 2029, 2034 (%)
  • Figure 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 18 Recombinant Non-Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 20 Human Growth Hormone Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 22 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 24 Insulin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 26 Interferon Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 28 Recombinant Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 30 Erythropoietin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 32 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Follitropin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Low Molecular Weight Heparin Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Biosimilars and Follow-On Biologics Market by Application: Market Attractiveness Index
  • Figure 38 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 39 Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 40 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 41 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Neutropenia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 44 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Anemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 51 Lung Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 53 Brain Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 55 Breast Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 57 Cervical Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 59 Colorectal Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 60 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 61 Leukemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 62 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 63 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 64 Autoimmune Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 65 Autoimmune Disease Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 66 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 67 Arthritis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 68 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 69 Inflammatory Bowel Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 70 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 71 Psoriasis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 74 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Growth Hormone Deficiency Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 76 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 77 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 78 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 79 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 80 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
  • Figure 81 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 82 Biosimilars and Follow-On Biologics Market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 83 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Recombinant DNA (rDNA) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 85 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 86 Monoclonal Antibodies (MAb) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 87 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
  • Figure 88 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 89 Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024, 2029, 2034 (%)
  • Figure 90 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Contract Research and Manufacturing Services Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 92 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 93 In-house Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 94 Biosimilars and Follow-On Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 95 Biosimilars and Follow-On Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 96 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 97 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 98 North America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 99 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 100 North America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 101 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 102 North America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 103 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 104 North America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 105 North America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 106 North America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 107 North America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 108 North America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 109 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 112 Europe Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 113 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 115 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 117 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 118 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 119 Europe Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Europe Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 121 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 123 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 124 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 125 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 133 Asia Pacific Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 134 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 135 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 136 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 137 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 138 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 139 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 140 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 141 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 142 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 143 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 144 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 145 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 146 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 149 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 150 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 151 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 152 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 153 Latin America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 154 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 155 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 156 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 157 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 158 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 159 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 160 Latin America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 161 Latin America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 162 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 163 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 164 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 165 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 166 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 167 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 168 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 169 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 170 MEA Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 171 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 172 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 173 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 174 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 175 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 176 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 177 MEA Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 178 MEA Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 179 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 180 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 181 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 182 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 183 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 184 Biosimilars and Follow-On Biologics Market: Company Share
  • Figure 185 Amgen Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 186 Amgen Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 187 Amgen Inc.: Regional Market Shares, 2023
  • Figure 188 Biocon Biologics Ltd.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 189 Biocon Biologics Ltd.: Regional Market Shares, 2023
  • Figure 190 Coherus Biosciences: Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 191 Fresenius Kabi (Fresenius SE & Co. KGaA): Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 192 Fresenius Kabi (Fresenius SE & Co. KGaA): Regional Market Shares, 2023
  • Figure 193 Pfizer: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 194 Pfizer R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 195 Pfizer Regional Market Shares, 2023
  • Figure 196 Sandoz Group AG: Net Revenue, 2022-2023 (US$ Million, AGR%)
  • Figure 197 Sandoz Group AG: Regional Market Shares, 2023
  • Figure 198 Teva Pharmaceuticals Industries Ltd: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 199 Teva Pharmaceuticals Industries Ltd: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 200 Teva Pharmaceuticals Industries Ltd: Regional Market Shares, 2023
目次
Product Code: PHA1332

The global Biosimilars and Follow-on Biologics market is projected to grow at a CAGR of 14.8% by 2034

The Biosimilars and Follow-on Biologics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand of Drugs For Treating Chronic Conditions

The increasing demand for drugs stems from their remarkable efficacy in treating a wide array of chronic and complex diseases, ranging from cancer to autoimmune disorders and beyond. Chronic conditions such as diabetes, rheumatoid arthritis, and various forms of cancer are becoming increasingly prevalent, driving up the need for effective long-term treatments. This surge is propelled by various factors, including the aging population, the prevalence of lifestyle-related ailments, and advancements in medical science enabling earlier detection and prolonged treatment.

As our understanding of disease mechanisms deepens, biologics continue to be at the forefront of medical innovation, offering hope for patients with previously untreatable conditions. Additionally, heightened awareness and evolving healthcare policies advocating proactive management of chronic illnesses further contribute to the increasing demand for these drugs.

Favourable regulatory policies for approval of biosimilars

Regulatory agencies around the world have recognized the importance of establishing clear and transparent pathways for the approval of biosimilars, ensuring that these products meet stringent standards of quality, safety, and efficacy.

One of the key elements of favourable regulatory policies is the establishment of specific guidelines and frameworks tailored to the unique characteristics of biosimilars. Unlike small molecule drugs, which can be replicated with relative ease, biologics are large, complex molecules produced in living cells, making their development and characterization more challenging. Regulatory pathways allow biosimilar manufacturers to rely on existing clinical data for reference biologics, expediting the approval process while still requiring robust comparative analytical and clinical studies to demonstrate similarity and safety. By providing clear expectations and requirements, these guidelines enable manufacturers to navigate the regulatory process more efficiently and effectively, accelerating the development and approval of biosimilars.

Moreover, favourable regulatory policies include provisions to expedite the review and approval of biosimilar products, fostering competition and expanding patient access to affordable treatments. Regulatory agencies may employ mechanisms such as abbreviated pathways or priority review designations to streamline the approval process for biosimilars, particularly for products targeting diseases with significant unmet medical needs. These expedited pathways help bring biosimilar products to market more quickly, encouraging innovation and investment in the biosimilars space.

What Questions Should You Ask before Buying a Market Research Report?

How is the Biosimilars and Follow-on Biologics Market evolving?

What is driving and restraining the Biosimilars and Follow-on Biologics Market?

How will each Biosimilars and Follow-on Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Biosimilars and Follow-on Biologics submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Biosimilars and Follow-on Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Biosimilars and Follow-on Biologics projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Biosimilars and

Follow-on Biologics projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Biosimilars and Follow-on Biologics Market?

Where is the Biosimilars and Follow-on Biologics Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biosimilars and Follow-on Biologics market today, and over the next 10 years:

Our 391-page report provides 156 tables and 200 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Biosimilars and Follow-on Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Biosimilars and Follow-on Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Product Type

Recombinant Non-Glycosylated Proteins

Human Growth Hormone

Granulocyte Colony-Stimulating Factor (Filgrastim)

Insulin

Interferon

Recombinant Glycosylated Proteins

Erythropoietin

Monoclonal Antibodies (Infliximab, Rituximab, Adalimumab, Trastuzumab, Bevacizumab, Etanercept)

Follitropin

Low Molecular Weight Heparin

Application

Hematology

Neutropenia

Anemia

Others

Oncology

Lung Cancer

Brain Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Leukemia

Others

Autoimmune Disease

Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Others)

Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Diseases, Others)

Psoriasis

Others

Growth Hormone Deficiency

Diabetes

Others

Technology

Recombinant DNA (rDNA) Technology

Monoclonal Antibodies (MAb) Technology

Manufacturer

Contract Research and Manufacturing Services

In-house

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Biosimilars and Follow-on Biologics Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Amgen Inc.

Apotex (Apobiologix)

Biocad

Biocon Biologics Ltd.

Bio-Thera Solutions

Coherus Biosciences

Dr. Reddy's Laboratories

Fresenius Kabi (Fresenius SE & Co. KGaA)

Intas Pharma

Pfizer

Reliance Life Sciences

Samsung Bioepis (Samsung Biologics)

Sandoz Group AG

Teva Pharmaceuticals Industries Ltd.

Overall world revenue for Biosimilars and Follow-on Biologics Market, 2024 to 2034 in terms of value the market will surpass US$33,000 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilars and Follow-on Biologics Market, 2024 to 2034 report help you?

In summary, our 390+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Biosimilars and Follow-on Biologics Market, 2024 to 2034, with forecasts for product type, application, technology and manufacturer each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 28 key national markets - See forecasts for the Biosimilars and Follow-on Biologics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Argentina, Germany, France, UK, Spain, Italy, Russia, Poland, Belgium, China, India, Japan, Australia, South Korea, Singapore, Taiwan, GCC, and South Africa among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Biosimilars and Follow-on Biologics Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Biosimilars and Follow-On Biologics Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Expiration of Patents for Original Biologics in the recent years
      • 3.2.1.2 Increasing Incidence of Chronic Diseases
      • 3.2.1.3 Established Clear Guidelines for the Approval of Biosimilars
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 High Development Costs of follow-on biologics
      • 3.2.2.2 Lack of Interchangeability Between Biosimilars and Their Reference Biologics
      • 3.2.2.3 Intellectual Property Issues and Other Legal Challenges
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Development of Biosimilar Versions of Monoclonal Antibodies
      • 3.2.3.2 Growing Demand for Affordable Biologics in Emerging Markets
      • 3.2.3.3 Expanding the Portfolio of Biosimilars for Rare Diseases
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Biosimilars Revenue by Region
    • 3.4.1 Worldwide
    • 3.4.2 United States
    • 3.4.3 Japan
  • 3.5 Biosimilars Latest Expected Approvals
    • 3.5.1 United States
    • 3.5.2 Europe
  • 3.6 Latest Biosimilar Product Deals
  • 3.7 List of Approved Biosimilars
  • 3.8 List of Recently Launched Biosimilars
  • 3.9 Porter's Five Forces Analysis
    • 3.9.1 Bargaining Power of Suppliers
    • 3.9.2 Bargaining Power of Buyers
    • 3.9.3 Competitive Rivalry
    • 3.9.4 Threat of Substitutes
    • 3.9.5 Threat of New Entrants
  • 3.10 PEST Analysis

4 Biosimilars and Follow-On Biologics Market Analysis by Product Type

  • 4.1 Key Findings
  • 4.2 Product Type Segment: Market Attractiveness Index
  • 4.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 4.4 Recombinant Non-Glycosylated Proteins
    • 4.4.1 Recombinant Non-Glycosylated Proteins Market by Product Type
    • 4.4.2 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.3 Market Share by Region, 2024 & 2034 (%)
    • 4.4.4 Human Growth Hormone
      • 4.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.5 Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.6 Insulin
      • 4.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.6.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.7 Interferon
      • 4.4.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Recombinant Glycosylated Proteins
    • 4.5.1 Recombinant Glycosylated Proteins Market by Product Type
    • 4.5.2 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.3 Market Share by Region, 2024 & 2034 (%)
    • 4.5.4 Erythropoietin
      • 4.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.5 Monoclonal Antibodies
      • 4.5.5.1 Market Size by Monoclonal Antibodies, 2024-2034 (US$ Million)
      • 4.5.5.2 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.5.3 Market Share by Region, 2024 & 2034 (%)
    • 4.5.6 Follitropin
      • 4.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.6.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.7 Low Molecular Weight Heparin
      • 4.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.7.2 Market Share by Region, 2024 & 2034 (%)

5 Biosimilars and Follow-On Biologics Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Product Type Segment: Market Attractiveness Index
  • 5.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 5.4 Hematology
    • 5.4.1 Hematology Market Forecast by Type
    • 5.4.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.3 Market Share by Region, 2024 & 2034 (%)
    • 5.4.4 Neutropenia
      • 5.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.5 Anemia
      • 5.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.6 Others
      • 5.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Oncology
    • 5.5.1 Oncology Market Forecast by Type
    • 5.5.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.3 Market Share by Region, 2024 & 2034 (%)
    • 5.5.4 Lung Cancer
      • 5.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.4.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.5 Brain Cancer
      • 5.5.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.5.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.6 Breast Cancer
      • 5.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.6.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.7 Cervical Cancer
      • 5.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.7.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.8 Colorectal Cancer
      • 5.5.8.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.8.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.9 Leukemia
      • 5.5.9.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.9.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.10 Others
      • 5.5.10.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Autoimmune Disease
    • 5.6.1 Autoimmune Disease Market Forecast by Type
    • 5.6.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.4 Arthritis
      • 5.6.4.1 Market Size by Type, 2024-2034 (US$ Million)
      • 5.6.4.2 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.4.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.5 Inflammatory Bowel Disease
      • 5.6.5.1 Market Size by Type, 2024-2034 (US$ Million)
      • 5.6.5.2 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.5.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.6 Psoriasis
      • 5.6.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.6.2 Market Share by Region, 2024 & 2034 (%)
    • 5.6.7 Others
      • 5.6.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Growth Hormone Deficiency
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Diabetes
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Biosimilars and Follow-On Biologics Market Analysis by Technology

  • 6.1 Key Findings
  • 6.2 Technology Segment: Market Attractiveness Index
  • 6.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Technology
  • 6.4 Recombinant DNA (rDNA) Technology
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Monoclonal Antibodies (MAb) Technology
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Biosimilars and Follow-On Biologics Market Analysis by Manufacturer

  • 7.1 Key Findings
  • 7.2 Product Type Segment: Market Attractiveness Index
  • 7.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 7.4 Contract Research and Manufacturing Services
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 In-house
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 Biosimilars and Follow-On Biologics Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Biosimilars and Follow-On Biologics Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 9.3 North America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 9.5 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 9.6 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 9.7 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 9.8 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 9.9 U.S. Biosimilars and Follow-On Biologics Market Analysis
  • 9.10 Canada Biosimilars and Follow-On Biologics Market Analysis

10 Europe Biosimilars and Follow-On Biologics Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 10.3 Europe Biosimilars and follow-on biologics market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 10.5 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 10.6 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 10.7 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 10.8 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 10.9 Germany Biosimilars and Follow-On Biologics Market Analysis
  • 10.10 France Biosimilars and Follow-On Biologics Market Analysis
  • 10.11 UK Biosimilars and Follow-On Biologics Market Analysis
  • 10.12 Italy Biosimilars and Follow-On Biologics Market Analysis
  • 10.13 Spain Biosimilars and Follow-On Biologics Market Analysis
  • 10.14 Russia Biosimilars and Follow-On Biologics Market Analysis
  • 10.15 Poland Biosimilars and Follow-On Biologics Market Analysis
  • 10.16 Belgium Biosimilars and Follow-On Biologics Market Analysis
  • 10.17 Rest of Europe Biosimilars and Follow-On Biologics Market Analysis

11 Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 11.3 Asia Pacific Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 11.6 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 11.7 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 11.8 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 11.9 Japan Biosimilars and Follow-On Biologics Market Analysis
  • 11.10 China Biosimilars and Follow-On Biologics Market Analysis
  • 11.11 India Biosimilars and Follow-On Biologics Market Analysis
  • 11.12 Australia Biosimilars and Follow-On Biologics Market Analysis
  • 11.13 South Korea Biosimilars and Follow-On Biologics Market Analysis
  • 11.14 Singapore Biosimilars and Follow-On Biologics Market Analysis
  • 11.15 Taiwan Biosimilars and Follow-On Biologics Market Analysis
  • 11.16 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

12 Latin America Biosimilars and Follow-On Biologics Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 12.3 Latin America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 12.5 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 12.6 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 12.7 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 12.8 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 12.9 Brazil Biosimilars and Follow-On Biologics Market Analysis
  • 12.10 Mexico Biosimilars and Follow-On Biologics Market Analysis
  • 12.11 Argentina Biosimilars and Follow-On Biologics Market Analysis
  • 12.12 Colombia Biosimilars and Follow-On Biologics Market Analysis
  • 12.13 Rest of Latin America Biosimilars and Follow-On Biologics Market Analysis

13 MEA Biosimilars and Follow-On Biologics Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 13.3 MEA Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 13.5 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 13.6 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 13.7 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 13.8 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 13.9 GCC Biosimilars and Follow-On Biologics Market Analysis
  • 13.10 South Africa Biosimilars and Follow-On Biologics Market Analysis
  • 13.11 Rest of MEA Biosimilars and Follow-On Biologics Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Amgen Inc.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2023
      • 14.3.3.2 R&D, 2017-2023
      • 14.3.3.3 Regional Market Shares, 2023
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Apotex (Apobiologix)
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Product Benchmarking
    • 14.4.4 Strategic Outlook
  • 14.5 Biocad
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 Biocon Biologics Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2023
      • 14.6.3.2 Regional Market Shares, 2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Bio-Thera Solutions
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 Coherus Biosciences
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2019-2023
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Dr. Reddy's Laboratories
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Fresenius Kabi (Fresenius SE & Co. KGaA)
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2019-2023
      • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Intas Pharma
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Strategic Outlook
  • 14.12 Pfizer
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2023
      • 14.12.3.2 R&D, 2017-2023
      • 14.12.3.3 Regional Market Shares, 2023
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Reliance Life Sciences
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
    • 14.13.4 Strategic Outlook
  • 14.14 Samsung Bioepis (Samsung Biologics)
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Sandoz Group AG
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2022-2023
      • 14.15.3.2 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Teva Pharmaceuticals Industries Ltd.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2023
      • 14.16.3.2 R&D, 2017-2023
      • 14.16.3.3 Regional Market Shares, 2023
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players